AstraZeneca PLC / KuDOS Pharmaceuticals Limited

BRCA-mutant / HRD-driven solid tumors (ovarian, breast, prostate, pancreatic)

Disease Overview

Cancers harboring BRCA1/2 mutations or broader homologous-recombination deficiency (HRD) cannot effectively repair double-strand DNA breaks. PARP inhibition exploits this 'synthetic lethality' — blocking the alternative single-strand repair pathway selectively kills HRD-defective tumor cells while sparing normal cells. The biology underpins olaparib's later approvals across BRCA-mutant ovarian, breast, pancreatic, and prostate cancers.

Competitive Landscape

At the time of the December 2005 KuDOS acquisition, the PARP inhibitor field was nascent and pre-clinical to early-clinical. KuDOS' KU-0059436 (later olaparib/Lynparza) was the most advanced clinical candidate, with first-in-human studies just initiated. Competitors in DNA-damage response (DDR) were primarily academic or early-stage: Pfizer was developing rucaparib (later sold to Clovis Oncology and approved in 2016), Sanofi-Aventis had iniparib (later failed), Abbott had veliparib in early development, and BiPar Sciences was developing what became iniparib. The $210M cash purchase gave AstraZeneca undisputed first-mover positioning in PARP and DDR — olaparib became the first PARP inhibitor approved (FDA, December 2014) for BRCA-mutant advanced ovarian cancer and went on to generate >$3B in annual sales by the early 2020s, validating the deal as one of the most accretive oncology platform acquisitions of the decade. The KuDOS deal also seeded AstraZeneca's broader DDR franchise (selumetinib, ATR inhibitor ceralasertib) and the Merck co-development partnership announced in 2017.